Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-03-07
2008-09-09
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Reexamination Certificate
active
07422747
ABSTRACT:
A method of inducing partial or complete immunity to an infectious disease in a mammal comprising providing to the mammal for oral consumption an effective amount of a protein complex comprising five monomeric fusion proteins.
REFERENCES:
patent: 4879113 (1989-11-01), Smith
patent: 4956282 (1990-09-01), Goodman et al.
patent: 5079165 (1992-01-01), Clements et al.
patent: 5098998 (1992-03-01), Mekalanos et al.
patent: 5268276 (1993-12-01), Holmgren et al.
patent: 5308835 (1994-05-01), Clements
patent: 5484719 (1996-01-01), Lam et al.
patent: 5589384 (1996-12-01), Lipscombe et al.
patent: 5612487 (1997-03-01), Lam et al.
patent: 5628994 (1997-05-01), Kaper et al.
patent: 5654184 (1997-08-01), Curtiss, III et al.
patent: 5679880 (1997-10-01), Curtiss, III et al.
patent: 5681571 (1997-10-01), Holmgren et al.
patent: 5686079 (1997-11-01), Curtiss, III et al.
patent: 5698416 (1997-12-01), Wolf et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5869057 (1999-02-01), Rock
patent: 5891432 (1999-04-01), Hoo
patent: 5917026 (1999-06-01), Löwenadler et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6030624 (2000-02-01), Russell et al.
patent: 6036953 (2000-03-01), Ryan et al.
patent: 6110724 (2000-08-01), Nakagomi et al.
patent: 6194560 (2001-02-01), Arntzen et al.
patent: 6395964 (2002-05-01), Arntzen et al.
patent: 6589529 (2003-07-01), Choi et al.
patent: 0437320 (1991-07-01), None
patent: WO9200099 (1992-01-01), None
patent: WO9310246 (1993-05-01), None
patent: WO9508347 (1995-03-01), None
patent: WO9508633 (1995-03-01), None
patent: WO9611708 (1996-04-01), None
patent: WO 96/12801 (1996-05-01), None
patent: WO9626218 (1996-08-01), None
patent: WO9823763 (1998-06-01), None
patent: WO09954452 (1999-10-01), None
Gonzalez et al, Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit. Gene. Nov. 15, 1993;133(2):227-32.
Shi et al, Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein. Vaccine. Jul. 1995;13(10):933-7.
Plotkin et al (Vaccines WB Saunders Company 1988, p. 571).
Arakawa, T. et al., “A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes,”Nature Biotechnology, 16:934-938, Oct. 1998.
Arakawa, T., “Suppression of Autoimmune Diabetes by a Plant-Delivered Cholera Toxin B Subunit-Human Glutamate Decarboxylase Fusion Protein,”Transgenics, 3:51-60 (1999).
Arakawa, T. et al., “Expression of cholera toxin B-subunit oligomers in transgenic potato plants,”Transgenic Research, 6:403-413, 1997.
Bergerot,. et al., “A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes,”Proc. Nat'l. Acad. Sci. USA, 94:4610-4614 (Apr. 1997).
De Neve, M. et al., Gene silencing results in instability of antibody production in transgenic plants,Mol. Gen. Genet, 260:582-592 (1999).
Dertzbaugh, M. et al., “Comparative Effectiveness of the Cholera Toxin B Subunit and Alkaline Phosphatase as Carriers for Oral Vaccines,”Infection and Immunity, 61(1):48-55 (Jan. 1993).
Doherty, P.C. et al., “CD8+ T-cell memory to viruses,”Current Opinion in Immunology, 6:545-552 (1994).
Fromm et al., “Inheritance and Expression of Chimeric Genes in the Progeny of Transgenic Maize Plants,”Biotechnology, vol. 8, 1990, pages.
Gilbert, S.C. et al., “A protein particle vaccine containing multiple malaria epitopes,”Nature Biotechnology, 15:1280-1284 (Nov. 1997).
Hajishengallis G. et al., “Muscosal Immunication With a Bacterial Protein Antigen Genetically Coupled to Cholera Toxin A2/B Subunits,” Journal of Immunology, The Williams and Wilkins Co., Baltimore, MD, vol. 154, No. 9, 1995, pp. 4322-4332.
Hao, T. et al., “Oral Immunization with a Recombinant Bacterial Antigen Produced in Transgenic Plants,”Science, 268:714-716 (May 1995).
Hardy,S.J.S. et al., “Coordinated assembly of multisubunit proteins: Oligomerization of bacterial enterotoxins in vivo and in vitro,”Proc. Natl. Acad. Sci. USA, 85:7109-7113 (Oct. 1988).
Hein, M.B. et al., “Expression of Cholera Toxin Subunits in Plants,”Annuals of New York Academy of Sciences, 792:50-56 (May 1996).
Holgren, J. et al., “Strategies for the Induction of Immune Responses at Mucosal Surfaces Making Use of Cholera Toxin B Subunit as Immunogen, Carrier, and Adjuvant,”Am. J. Prop. Med. Hyg., 42-54 (1994).
Jackson, Raymond J., “Optimizing Oral Vaccines: Induction of Systemic and Mucosal B-Cell and Antibody Responses to Tetanus Toxoid by use of Cholera Toxin as an Adjuvant,”Infection and Immunity, 61(10):4272-4279 (Oct. 1993).
Jefferson, Richard et al., “GUS fusions: β-glucuronidse as a sensitive and versatile gene fusion marker in higher plants,”EMBO Journal, 6(13):3901-3907 (Dec. 1987).
Liljeqvist S. et al., “Production of Recombinant Subunit Vaccines: Protein Immunogens, Live Delivery Systems and Nucleic Acid Vaccines,” Journal of Biotechnology, Elsevier Science Publishers, Amsterdam, NL, vol. 73, No. 1, 1999, pp. 1-33.
Lowe, Keith et al., “Germline Transformation of Maize Following Manipulation of Chimeric Shoot Meristems,”Biotechnology, 13:677-682 (Jul. 1995).
Ma, S.W., “Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance,”Nature Medicine, 3(7):793-796 (Jul. 1997).
Mason, H.S., “Transgenic plants as vaccine production systems,”Tibtech, 13:388-392 (Sep. 1995).
McInerney, T.L. et al., “Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide,”Vaccine, 17:1359-1368 (1999).
Modelska, Anna et al., “Immunization against rabies with plant-derived antigen”,Proc. Natl. Acad. Sci. USA, 95:2481-2485 (Mar. 1998).
Mowat, A.M., “Oral tolerance therapy fundamental and practical aspects,”Chemistry&Industry, pp. 10-9 (Nov. 1996).
Nashar,T.O. et al., “Current progress in the development of the B subunits of cholera toxin andEscherichia coliheat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes,”Vaccine, 11(2):235-240 (1993).
Schon, A. et al., “Thermodynamics of Intersubunit Interactions in Cholera Toxin upon Binding to the Oligosaccharide Portion of Its Cell Surface Receptor, Ganglioside GM1”Biochemistry, 28:5019-5024 (1989).
Sedlik, C. et al., “Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells,”Proc. Natl. Acad. Sci. USA, 94:7503-7508 (Jul. 1997).
Simone, E.A. et al., “Immunologic ‘Vaccination’ for the Prevention of Autoimmune Diabetes (Type 1A),”Diabetes Care, 22(2):B7-B15 (Mar. 1999).
Spangler, B.D., “Structure and Function of Cholera Toxin and the RelatedEscherichia coliHeat-Labile Enterotoxin,”Microbiological Reviews, 56:(4)622-647 (Dec. 1992).
Sun, J., et al., “Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance,”Proc. Natl. Acad. Sci. USA, 91:10795-10799 (Nov. 1994).
Williams, Neil A. et al., “Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic,”Immunology Today,(Feb. 1999).
Arakawa Takeshi
Langridge William H. R.
Yu Jie
Farah David A.
Loma Linda University
Navarro Mark
Sheldon Mak Rose & Anderson PC
LandOfFree
Transgenic plant-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic plant-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic plant-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986502